These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
155 related items for PubMed ID: 35810311
21. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348 [Abstract] [Full Text] [Related]
22. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, Hawkins PN, Jager PL. Am J Med; 2006 Apr; 119(4):355.e15-24. PubMed ID: 16564782 [Abstract] [Full Text] [Related]
23. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. Hawkins PN, Lavender JP, Pepys MB. N Engl J Med; 1990 Aug 23; 323(8):508-13. PubMed ID: 2377176 [Abstract] [Full Text] [Related]
25. Prevalence and origin of amyloid in kidney biopsies. von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Röcken C. Am J Surg Pathol; 2009 Aug 23; 33(8):1198-205. PubMed ID: 19561448 [Abstract] [Full Text] [Related]
27. Pathology and diagnosis of renal non-AL amyloidosis. Sethi S, Theis JD. J Nephrol; 2018 Jun 23; 31(3):343-350. PubMed ID: 28828707 [Abstract] [Full Text] [Related]
28. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. Hawkins PN, Wootton R, Pepys MB. J Clin Invest; 1990 Dec 23; 86(6):1862-9. PubMed ID: 2254450 [Abstract] [Full Text] [Related]
29. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Hawkins PN, Tennent GA, Woo P, Pepys MB. Clin Exp Immunol; 1991 May 23; 84(2):308-16. PubMed ID: 1673879 [Abstract] [Full Text] [Related]
30. Amyloid Signature Proteins in Feline Amyloidosis. Miyazaki S, Kadota A, Mitsui I, Murakami T. J Comp Pathol; 2020 May 23; 177():10-17. PubMed ID: 32505236 [Abstract] [Full Text] [Related]
31. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Hawkins PN, Aprile C, Capri G, Viganò L, Munzone E, Gianni L, Pepys MB, Merlini G. Eur J Nucl Med; 1998 Jul 23; 25(7):701-8. PubMed ID: 9662591 [Abstract] [Full Text] [Related]
36. Targeted treatment for amyloidosis. Pepys-Vered ME, Pepys MB. Isr Med Assoc J; 2014 May 23; 16(5):277-80. PubMed ID: 24979830 [No Abstract] [Full Text] [Related]
37. Demonstration and classification of amyloidosis in needle biopsies of the kidneys, with special reference to amyloidosis of the AA-type. Löfberg H, Thysell H, Westman K, Larsen S, Brun C, Gruic V, Grubb A. Acta Pathol Microbiol Immunol Scand A; 1987 Nov 23; 95(6):357-63. PubMed ID: 3120491 [Abstract] [Full Text] [Related]
38. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Shah PL, Gillmore JD, Copley SJ, Collins JV, Wells AU, du Bois RM, Hawkins PN, Nicholson AG. Sarcoidosis Vasc Diffuse Lung Dis; 2002 Jun 23; 19(2):134-42. PubMed ID: 12102609 [Abstract] [Full Text] [Related]
39. The Paradoxical Effects of Serum Amyloid-P Component on Disseminated Candidiasis. Klotz SA, Lipke PN. Pathogens; 2022 Nov 06; 11(11):. PubMed ID: 36365055 [Abstract] [Full Text] [Related]
40. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, Pugh CW, Winearls CG, Oliver DO, Pepys MB. Lancet; 1991 Aug 10; 338(8763):335-9. PubMed ID: 1677697 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]